杨悦 - 清华大学

个人简介

杨悦本硕博毕业于沈阳药科大学，2004年获得沈阳药科大学药学博士学位，是我国第一位药事管理方向的药学博士学位获得者。曾任沈阳药科大学教授，博士生导师（2011.11-2020.9）。2020年10月，加入清华大学药学院，担任研究员，博士生导师（药学一级学科下社会与管理药学招生）。现为药品监管科学学科带头人，清华大学药学院药品监管科学研究院院长，国家药品监督管理局创新药物研究与评价重点实验室主任。海南大学兼职博士生导师（与海南省真实世界数据研究院联合培养硕士和博士），国家医疗保障局医药价格与招标采购专家组专家。

研究领域

主要从事药品监管科学以及药物政策和制度的顶层设计，监管路径和程序优化研究，以及评价创新药、仿制药（生物类似药）、罕见病用药等的安全性、有效性和质量等的新工具、新标准、新方法研究等。研究范围涵盖药品的全生命周期。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Luo X, Guo Q, Du X, Huang L, Chow SC*, Yang Y*. Evaluation of clinical trial designs for novel anticancer drugs in China: a cohort study of drugs approved between 2015 and 2021. Drug Discov Today. 2023 Mar 31:103578. Luo X, Du X, Huang L, Guo Q, Tan R, Zhou Y, Li Z, Xue X, Li T, Le K, Qian F, Chow SC*, Yang Y*. The price, efficacy, and safety of within-class targeted anticancer medicines between domestic and imported drugs in China: a comparative analysis. Lancet Reg Health West Pac. 2022;32:100670. Luo X, Du X, Li Z, Qian F, Yang Y*. Assessment of the Delay in Novel Anticancer Drugs between China and the United States: A Comparative Study of Drugs Approved between 2010 and 2021. Clin Pharmacol Ther. 2023;113(1):170-181. Luo X, Yang L, Du X, Yang J, Qian F, Yang Y*. Analysis of Patent and Regulatory Exclusivity for Novel Agents in China and the United States: A Cohort Study of Drugs Approved Between 2018 and 2021. Clin Pharmacol Ther. 2022;112(2):335-343. Luo X, Qian F, Yang L, Li Y, Yang Y*. Assessment of the breakthrough-therapy-designated drugs granted in China: A pooled analysis 2020-2022. Drug Discov Today. 2022;27(12):103370. Li Y, Jiang Y, Wang H, Zhang L, Yang Y*. Safety-Related Drug Withdrawals in China Between 1999 and 2021: A Systematic Investigation and Analysis. Drug Saf 45, 737–745 (2022). Chen, S., Chen, X., Liu, M, Xu Z, Yang Y*. Regulation of Generic Drugs in China: Progress and Effect of the Reform of the Review and Approval System. J Pharm Innov (2022). Aslam F, Babar ZU, Madni A, Asghar M, Yang Y*. Unveiling and addressing implementation barriers of vaccination communication strategy: Perspectives from government officials at national and provincial levels. Hum Vaccin Immunother. 2022 Dec 30;18(7):2153513. Aslam F, Ali I, Babar Z, Yang Y. Building evidence for improving vaccine adoption and uptake of childhood vaccinations in low- and middle-income countries: a systematic review. Drugs Ther Perspect. 2022;38(3):133-145. Li, X., Yang, Y. The drug lag issue: a 20-year review of China. Invest New Drugs 39, 1389–1398 (2021).